search
ImmunityBio
Trends
- 1Retail Traders Eye SLS, IBRX After Moderna's Nasdaq-100 Entry▼SLS, IBRX Stocks Draw Retail Chatter As MRNA Lands A Nasdaq-100 Spot – ‘It Will Be SLS Next’
Retail investors are speculating about small-cap biotech stocks Sellas Life Sciences (SLS) and ImmunityBio (IBRX) after Moderna (MRNA) was added to the Nasdaq-100 index. Some traders are betting one of the two could be next to earn a spot in the benchmark index, fueling buzz around the names on social trading platforms. Index inclusion typically drives demand from funds tracking the Nasdaq-100, which is why traders watch additions closely for potential stock moves.
- 2Retail biotech favorites SLS, IBRX, VNDA, IOVA vs September slump▼Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
Biotech stocks lagged the broader market in September, with the SPDR S&P Biotech ETF (XBI) falling while the wider market held up better. Attention is now on whether retail-favored names SELLAS Life Sciences (SLS), ImmunityBio (IBRX), Vanda Pharmaceuticals (VNDA) and Iovance Biotherapeutics (IOVA) managed to escape the sector's slump. Investors are weighing whether these popular small-cap biotechs diverged from the wider sector weakness.